Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B02 ANTIHEMORRHAGICS
B02B VITAMIN K AND OTHER HEMOSTATICS
B02BX Other systemic hemostatics
B02BX08 Avatrombopag
D10307 Avatrombopag maleate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Platelet Modifying Agents
Platelet Modifying Agents, Other
Avatrombopag
D10307 Avatrombopag maleate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D10307 Avatrombopag maleate (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01976 Avatrombopag
D10307 Avatrombopag maleate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01976 Avatrombopag
D10307 Avatrombopag maleate
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
CSF and other factor receptors
MPL (TPOR, CD110)
D10307 Avatrombopag maleate (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10307
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10307
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10307
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10307
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D10307
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01976 Avatrombopag
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01976 Avatrombopag